PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - PHAS

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - PHAS

  • Market Cap$83.630m
  • SymbolNASDAQ:PHAS
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINUS7172241090

Company Profile

PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension.

Latest PHAS news

Currently there for this company. Visit our news hub for other news .